[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors",
    "summary": "Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=0df9baab2c15116d653e1d956535ed06f8b9ace3feacbdd4cc4015326bcad2cf",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758300000,
      "headline": "Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors",
      "id": 136870578,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=0df9baab2c15116d653e1d956535ed06f8b9ace3feacbdd4cc4015326bcad2cf"
    }
  },
  {
    "ts": null,
    "headline": "Arvinas reboots, cuts more staff; Porges joins Lazard",
    "summary": "Pfizer and Arvinas plan to out-license their partnered drug vepdegestrant. Elsewhere, Novo shared more data for oral Wegovy and Vertex reached a deal in Italy for coverage of its gene editing medicine Casgevy.",
    "url": "https://finnhub.io/api/news?id=2a1cb1449022cead7cf7fe93a8d58116b1e362f699d68ca7725285eae9a45abe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758283560,
      "headline": "Arvinas reboots, cuts more staff; Porges joins Lazard",
      "id": 136820040,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Pfizer and Arvinas plan to out-license their partnered drug vepdegestrant. Elsewhere, Novo shared more data for oral Wegovy and Vertex reached a deal in Italy for coverage of its gene editing medicine Casgevy.",
      "url": "https://finnhub.io/api/news?id=2a1cb1449022cead7cf7fe93a8d58116b1e362f699d68ca7725285eae9a45abe"
    }
  }
]